Compare UTHR & IHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | IHG |
|---|---|---|
| Founded | 1996 | 1777 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 21.5B |
| IPO Year | 1999 | 2000 |
| Metric | UTHR | IHG |
|---|---|---|
| Price | $579.93 | $142.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $561.57 | N/A |
| AVG Volume (30 Days) | ★ 612.6K | 190.6K |
| Earning Date | 04-29-2026 | 08-02-2016 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 27.86 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $7.08 | $9.52 |
| Revenue Next Year | $14.32 | $5.51 |
| P/E Ratio | ★ $20.89 | $29.84 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $272.18 | $99.41 |
| 52 Week High | $607.89 | $150.89 |
| Indicator | UTHR | IHG |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 63.68 |
| Support Level | $464.92 | $128.00 |
| Resistance Level | $607.89 | $144.96 |
| Average True Range (ATR) | 18.49 | 2.87 |
| MACD | 1.72 | 1.37 |
| Stochastic Oscillator | 69.09 | 97.49 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
InterContinental Hotels Group operates 987,000 rooms across 20 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.